Articles On Oncosil Medical (ASX:OSL)

ASX gives back gains ahead of Fed decision Vulcan and DigiCo rise MinRes completes $780m gas deal with Hancock Prospecting   The ASX gave back its earlier gains this afternoon as investors adopted a more cautious approach ahead of the US...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

Harvard University’s teaching hospital will adopt Echo IQ’s AI-based aortic stenosis detection tool Immuron trots out its Travelan agenda at its AGM Oncosil goes hot and cold with latest distribution deals   Echo IQ (ASX:EIQ) has won the...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

The S&P/ASX 200 fell 1.3% in October with small cap companies outperforming S&P Dow Jones Indices said financials led the gains in October and is up 30% YTD Ovanti rose 525% in October after appointment of former Zip US CFO Simon K...

ASX ends very modestly lower after a mixed session Newmont and Fortescue shares drop on disappointing updates WiseTech continues its slide as investors start to grumble   Aussie shares swung to a flattish close today after earlier losses...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Health Check is renowned biotech journo Tim Boreham’s daily wrap covering morning movers and shakers of note in the ASX Healthcare sector, Monday through Thursday.   PYC Therapeutics notes a growing valuation chasm between the data-rich, p...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from James McDona...

‘Wheezo’ maker Respiri says a new US deal will help to propel the company to cash-flow break even by the end of the year Immutep reports further promising data from its head neck and shoulder cancer program Oncosil Medical targets the diff...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

ASX up as earnings season rolls on; Origin down 10pc, Telstra up 3pc Australia’s unemployment rate edged up to 4.2pc from 4.1pc Iron ore futures dropped below US$94 per ton   The ASX edged slightly higher by 0.1% on Thursday, boosted by a...

OncoSil Medical (ASX: OSL) has announced a 78% increase in the number of doses of its OncoSil single-use brachytherapy device used in commercial treatments for patients with pancreatic cancer, reflecting a growing adoption of the device in...

Oncosil Medical Ltd (ASX:OSL) has announced that a patient with pancreatic cancer was able to reduce their tumor through treatment with the company’s eponymous device in conjunction with chemotherapy during a procedure in Türkiye. Follow...

PYC starts human trials for PYC-001 to treat rare eye disease OncoSil device successfully treats first patient in Türkiye, enabling tumour removal    PYC to start human trials for rare eye disease PYC Therapeutics (ASX:PYC) has received a...

The ASX dropped, dragged down by Real Estate and Mining stocks Qantas cuts former CEO’s compensation by $9.3m Fears of a US recession are growing, with the Sahm Rule signalling potential trouble   A selloff in Real Estate and Mining stock...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

S&P/ASX 200 had its best month of the year in July finishing up 4% to record high S&P Dow Jones Indices says large cap companies continued to lead the market in July Consumer discretionary and real estate topped July sector leaders...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

ASX rises on Monday after Wall Street banked a belter on Friday All 11 local sectors higher, InfoTech winning the race for Best in Show Aruma Resources led the small caps winners   The local benchmark moved strongly into positive terri...

Good morning (just), and welcome to Stockhead’s Top 10 at shortly-after-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help fram...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has updated investors on the PANCOSIL clinical trial.

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

The ASX200 is down 1.1 per cent – on par with futures’ predictions – with every sector flashing red mid-session. Meanwhile, the ABS has released international investment data and living cost indexes. Australia’s International Investme...

OncoSil Medical (ASX:OSL) released groundbreaking findings from a study which showed that the addition of OncoSil™ to systemic chemotherapy returned an increase in the vascularity of the primary pancreatic tumors, and at the same time: resu...

  ASX to open sharply lower as Wall Street spooked by strong US jobs data Cannabis stocks jumped after the US DEA downscheduled pot Amazon popped on top and bottom lines beat   Aussie shares are poised to open sharply lower on Wednesday...

The ASX belts one out on Monday, up 0.8pc All 11 sectors are better for it Canterbury Resources grows by half   The benchmark Aussie index has started the week with decisive and broad based gains. All 11 sectors ended Monday higher. US Fu...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

The ASX pared gains after the CPI came in stronger than expected Fortescue led the Mining sector after its quarterly update TikTok’s ban in the US looms   The ASX closed modestly higher today by +0.1% as gains were pared after the release...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX extends its gains on Tuesday Tech stocks rallied ahead of US megacap earnings, while goldies struggled Tesla, along with Alphabet and Spotify, will release results tonight   The ASX200 lifted on Tuesday, up by +0.45% after trackin...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has announced the first treatment utilising the OncoSil device on a patient residing in Turkey.

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

OncoSil Medical (ASX:OSL), in its ongoing mission to develop treatments for pancreatic cancer, says the first patient treatment using the OncoSilTM device for its TRIPP-FXX clinical study has been conducted at the prestigious Hammersmith Ho...

The ASX200 closed up slightly by +0.1% on Monday as gains in tech and gold stocks were offset by losses in the energy sector.  Energy stocks struggled as crude prices fell more than US$1 a barrel in Asian hours today after Israel confirmed...

The ASX200 has closed down .56 of a per cent with IT down 1.4 per cent and in the red for a second straight day, materials slumping 0.8 per cent and real estate shedding .61 per cent. Coming into sharp focus today were OncoSil Medical, T...

The ASX200 is down nearly .7 of a per cent – almost on par with futures’ predictions – with most sectors, apart from energy, in the red. The Australian Bureau of Statistics released data showing that imported goods rose by 4.8 per cent i...

OncoSil Medical (ASX:OSL) – on its mission to combat pancreatic cancer – has now dosed the first two patients in Austria with the use of the OncoSilTM device. In early trade Oncosil shares catapulted as much as 30 per cent after announci...

The ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL  Small Caps led by Dart Mining and Mesoblast   Local stocks looked the goods during the first hour of the new quarter, but that – like the ASX200’s...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

The ASX200 has ended Friday down 0.15pc, but ends week higher Property and Healthcare gains offset by Resources losses  Small Caps led by Gold50   Wall Street hit more record highs on Thursday in New York, the Australian market on Friday,...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...